BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37865914)

  • 21. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
    Chung SY; Chang YC; Hsu DS; Hung YC; Lu ML; Hung YP; Chiang NJ; Yeh CN; Hsiao M; Soong J; Su Y; Chen MH
    Neoplasia; 2023 Jan; 35():100856. PubMed ID: 36442297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
    Ripp J; Hentzen S; Saeed A
    Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
    Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
    Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
    Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
    Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy.
    Li Q; Su R; Bao X; Cao K; Du Y; Wang N; Wang J; Xing F; Yan F; Huang K; Feng S
    Acta Biomater; 2022 May; 144():109-120. PubMed ID: 35314366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
    Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
    Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.
    Hwang WC; Song D; Lee H; Oh C; Lim SH; Bae HJ; Kim ND; Han G; Min DS
    Exp Mol Med; 2022 Sep; 54(9):1563-1576. PubMed ID: 36131027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
    Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
    Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
    Hijazi A; Antoniotti C; Cremolini C; Galon J
    Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
    Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 39. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
    Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
    [No Abstract]   [Full Text] [Related]  

  • 40. Dendritic polymer-functionalized nanomedicine potentiates immunotherapy via lethal energy crisis-induced PD-L1 degradation.
    Li X; Duan Z; Li Z; Gu L; Li Y; Gong Q; Gu Z; Luo K
    Biomaterials; 2023 Nov; 302():122294. PubMed ID: 37657175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.